ALKS completed enrollment in a Phase II trial that is testing safety and initial efficacy of intra-arterial administration.

Alkermes Inc. (ALKS), Cambridge, Mass. Product: RMP-7 delivery agent to cross the blood-brain barrier in combination with carboplatin Indication: Recurrent malignant brain tumor Status: ALKS completed...